Skip to main content
. Author manuscript; available in PMC: 2011 Apr 14.
Published in final edited form as: N Engl J Med. 2010 Oct 14;363(16):1510–1520. doi: 10.1056/NEJMoa1000931

Table 1.

Baseline Characteristics of the Children.*

Characteristic Nevirapine Group Ritonavir-Boosted Lopinavir Group Total Cohort
Children <12 mo (N = 60) Children ≥12 mo (N = 22) All Children (N = 82) Children <12 mo (N = 63) Children ≥12 mo (N = 19) All Children (N = 82) Total (N = 164)
Age — yr
 Median 0.6 1.5 0.7 0.6 1.5 0.7 0.7
 10th–90th percentile 0.5 to 0.9 1.1 to 2.2 0.5 to 1.6 0.5 to 0.8 1.2 to 2.6 0.5 to 1.7 0.5 to 1.7
Weight z score
 Median −1.2 −1.5 −1.3 −0.9 −1.1 −1.1 −1.1
 10th–90th percentile −3.2 to 0.8 −5.5 to −0.2 −3.7 to 0.5 −2.6 to 0.5 −3.4 to 0.2 −2.7 to 0.4 −3.3 to 0.4
Height z score
 Median −1.3 −1.8 −1.5 −0.9 −1.3 −1.0 −1.2
 10th–90th percentile −3.1 to 0.3 −3.1 to −0.2 −3.1 to 0.2 −2.5 to 0.4 −2.8 to 0.1 −2.5 to 0.1 −2.7 to 0.2
Percentage of CD4+ lymphocytes
 Median 19.2 16.9 18.9 21.1 15.2 19.7 19.0
 10th–90th percentile 12.0 to 31.4 9.8 to 27.1 10.5 to 30.7 14.0 to 30.6 7.3 to 33.0 9.7 to 30.6 10.4 to 30.7
HIV-1 RNA — log10 copies/ml
 Median 5.9 5.9 5.9 5.9 5.9 5.9 5.9
 10th–90th percentile 5.1 to 5.9 5.4 to 5.9 5.2 to 5.9 5.2 to 5.9 5.4 to 5.9 5.2 to 5.9 5.2 to 5.9
Male sex — no. (%) 28 (46.7) 8 (36.4) 36 (43.9) 31 (49.2) 10 (52.6) 41 (50.0) 77 (47.0)
Breast-fed — no. (%) 13 (21.7) 2 (9.1) 15 (18.3) 18 (28.6) 1 (5.3) 19 (23.2) 34 (20.7)
WHO disease stage — no. (%)
 1 5 (8.3) 0 5 (6.1) 16 (25.4) 3 (15.8) 19 (23.2) 24 (14.6)
 2 23 (38.3) 3 (13.6) 26 (31.7) 19 (30.2) 3 (15.8) 22 (26.8) 48 (29.3)
 3 27 (45.0) 11 (50.0) 38 (46.3) 25 (39.7) 12 (63.2) 37 (45.1) 75 (45.7)
 4 5 (8.3) 8 (36.4) 13 (15.9) 3 (4.8) 1 (5.3) 4 (4.9) 17 (10.4)
*

WHO denotes World Health Organization.

HIV-1 RNA levels were censored at the upper limit of the assay (5.9 log10 copies per milliliter).